NEW YORK ─ Brussels-based Flanders Innovation & Entrepreneurship (VLAIO) has awarded a €720,000 ($872,989) grant to Ohmx.bio and Fujirebio Europe to develop a clinical in vitro diagnostics platform that incorporates third-generation sequencing (TGS) technologies, the firms announced Tuesday.
The project, called IVD-seq, will initially focus on the development of a cost-efficient, accurate, and portable IVD modular platform for highly polymorphic regions, and then aim to expand to other molecular diagnostic markers, the companies said.